Hormone receptor status-Negative (ER-/PR-) Posts on Medivizor
Navigation Menu

Hormone receptor status-Negative (ER-/PR-) Posts on Medivizor

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Posted by on Apr 3, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICI) plus chemotherapy versus chemotherapy alone for the treatment of patients with triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was more effective than chemotherapy alone and was associated with a higher rate of side...

Read More

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Posted by on Feb 25, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of trilaciclib (Cosela) given before gemcitabine (Gemzar) plus capecitabine (Xeloda) (GC) chemotherapy regimen in patients with metastatic triple-negative breast cancer (mTNBC). The data showed that trilaciclib given before GC chemotherapy regimen was effective and significantly improved overall...

Read More

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Posted by on Dec 5, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of epirubicin (Ellence) and cyclophosphamide (Cytoxan) plus paclitaxel (Taxol)/docetaxel (Taxotere) (taxanes) (ECT) versus carboplatin (Paraplatin) plus taxanes (TP) regimens in patients with early-stage triple-negative breast cancer (TNBC). The data showed that both treatment regimens showed...

Read More

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Breast cancer | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...

Read More

Searching for patients with metastatic triple negative breast cancer to trial a cancer vaccine

Searching for patients with metastatic triple negative breast cancer to trial a cancer vaccine

Posted by on Nov 9, 2020 in Breast cancer | 0 comments

In a nutshell This study is looking to trial the addition of a new form of vaccine called a neoantigen vaccine in combination with nab–paclitaxel (Abraxane), duvalumab (Imfinzi), and tremelimumab (CP-675,206), in patients with metastatic triple-negative breast cancer (mTNBC). The main outcome that will be measured is survival without the...

Read More

Can adding capecitabine improve outcomes for patients with triple-negative breast cancer?

Posted by on Mar 29, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at adding capecitabine (Xeloda) to standard treatment for patients with triple-negative breast cancer (TNBC). It found that capecitabine improved outcomes for patients with TNBC. Some background Breast tissue growth responds to changing levels of the hormones estrogen and progesterone. Some breast cancer can...

Read More

Safety and effectiveness of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer

Posted by on Dec 17, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.  This study concluded that this combination was found to be safe and promising in these patients.  Some background Pembrolizumab (Keytruda) is a targeted...

Read More

Looking for patients with advanced triple negative breast cancer to test an experimental drug with three functions

Posted by on Oct 31, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with advanced triple-negative breast cancer. The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details...

Read More

Searching for patients with advanced triple-negative breast cancer to test a new combination treatment

Posted by on Aug 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...

Read More

Searching patients with triple-negative breast cancer to trial a new treatment combination

Posted by on Jul 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...

Read More

Looking patients with metastatic triple negative breast cancer to trial a radiation treatment

Posted by on Jun 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse).  This trial is recruiting in multiple locations in New York and New Jersey, US. The details...

Read More